ABO 503
Alternative Names: ABO-503Latest Information Update: 10 Aug 2023
At a glance
- Originator Abeona Therapeutics
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Retinoschisis
Most Recent Events
- 08 Aug 2023 Abeona Therapeutics plans to initiate IND-enabling studies in the second half of 2023
- 19 May 2023 Pharmacodynamics data from preclinical studies in Retinoschisis released by Abeona Therapeutics
- 10 Apr 2023 Abeona Therapeutics anticipates pre-IND meeting with the US FDA in the second quarter of 2023